Lv1
70 积分 2024-04-19 加入
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
25天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
25天前
已完结
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
1个月前
已完结
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
1个月前
已完结
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
1个月前
已完结
Analysis of the Complement System in the Clinical Immunology Laboratory
3个月前
已完结
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
4个月前
已完结
Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise
4个月前
已关闭
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
4个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
5个月前
已完结
皖公网安备34019202002308
